Invivyd, Inc. (NASDAQ:IVVD) Short Interest Up 8.4% in January

Invivyd, Inc. (NASDAQ:IVVD) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totalling 3,980,000 shares, an increase of 8.4% from the December 31st total of 3,670,000 shares. Based on an average daily volume of 958,500 shares, the short-interest ratio is currently 4.2 days. Currently, 5.3% of the shares of the company are short sold.

Insiders Place Their Bets

In other news, Director Terrance Mcguire sold 86,545 shares of the business’s stock in a transaction on Monday, December 30th. The shares were sold at an average price of $0.48, for a total transaction of $41,541.60. Following the completion of the sale, the director now owns 3,170,231 shares of the company’s stock, valued at $1,521,710.88. The trade was a 2.66 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In the last quarter, insiders sold 816,466 shares of company stock valued at $423,214. Company insiders own 17.90% of the company’s stock.

Institutional Trading of Invivyd

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. State Street Corp increased its position in shares of Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock valued at $1,039,000 after acquiring an additional 35,904 shares during the last quarter. Marshall Wace LLP raised its position in Invivyd by 4.2% in the 2nd quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock valued at $866,000 after purchasing an additional 31,992 shares during the last quarter. Renaissance Technologies LLC purchased a new stake in Invivyd in the 2nd quarter valued at $421,000. Cubist Systematic Strategies LLC raised its position in Invivyd by 66.1% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 134,452 shares of the company’s stock valued at $148,000 after purchasing an additional 53,499 shares during the last quarter. Finally, Barclays PLC raised its position in Invivyd by 179.6% in the 3rd quarter. Barclays PLC now owns 117,973 shares of the company’s stock valued at $120,000 after purchasing an additional 75,780 shares during the last quarter. Institutional investors and hedge funds own 70.36% of the company’s stock.

Invivyd Stock Performance

Shares of IVVD opened at $1.06 on Tuesday. Invivyd has a fifty-two week low of $0.35 and a fifty-two week high of $5.10. The company has a 50 day moving average price of $0.50 and a 200-day moving average price of $0.82. The stock has a market capitalization of $126.80 million, a PE ratio of -0.54 and a beta of 0.61.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. D. Boral Capital restated a “buy” rating and set a $9.00 target price on shares of Invivyd in a research note on Monday. EF Hutton Acquisition Co. I upgraded shares of Invivyd to a “strong-buy” rating in a research report on Wednesday, October 30th. Morgan Stanley decreased their target price on shares of Invivyd from $9.50 to $3.55 and set an “overweight” rating on the stock in a research report on Wednesday, November 20th. Finally, HC Wainwright cut their price target on shares of Invivyd from $15.00 to $10.00 and set a “buy” rating on the stock in a report on Wednesday, November 20th. Four equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $7.89.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.